





Aging is associated with various metabolic disorders 
that may have their origin in the liver, including obesity, 
type 2 diabetes mellitus, non-alcoholic fatty liver 
disease (NAFLD), and atherosclerosis [1,2]. These 
conditions are provoked by diverse factors, including 
reactive oxygen species, endoplasmic reticulum stress, 
hypoxia, lipotoxicity, and altered adipokine signaling 
[3-5]. In addition, saturated fatty acids, which are 
increased in obesity [5-8], have been implicated in the 
coordinate regulation of metabolism with inflammatory 
and immune responses in the liver [9-11].  
 
The mitochondrial proteome also changes with disease 
state. Recently, mitochondrial dysfunction has been 
implicated in the pathology of chronic metabolic 
disease characterized by insulin resistance such as 
obesity, type 2 diabetes mellitus, and aging.   
Acetylation has emerged as an important mechanism for 
controlling metabolism of a broad array of metabolic 
fuels. Acetylation regulates many enzymes in key 
pathways including TCA cycle, gluconeogenesis, and 
beta oxidation in yeast and human liver [12,13]. This 
post-translational  modification is governed,  in part,  by  
 
 






























sirtuins, class III NAD+-dependent deacetylases 
(HDACs) that regulate lipid and glucose metabolism in 
liver during fasting and aging. SIRT3, a mitochondrial 
sirtuin, appears to be the primary mediator of 
mitochondrial acetylation, since no significant changes 
in acetylation status are detectable in mice lacking 
SIRT4 and SIRT5 [14].   
 
Mice lacking SIRT3 show accelerated aging and 
liver phenotypes during fasting. 
 
All sirtuins require NAD+ for their deacetylase 
activities, linking their functions as metabolic sensors. 
For example, increased Nampt-mediated NAD 
biosynthesis enhances SIRT1 activity in mouse 
fibroblasts [15].  Nampt also plays an important part   
in regulating cellular stress resistance  through      
SIRT3 [16]. Under genotoxic stress, increased       
Nampt plays an important part in maintaining NAD 
levels in mitochondria and providing protection 
against cell death by suppressing translocation of 
apoptosis-inducing  factor  from  mitochondria  to        
the nucleus  [16].  These  protective  effects  of  Nampt  
Reduced mitochondrial function in obesity-associated fatty liver: 
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Previously it was shown that many mitochondrial 
proteins are hyperacetylated in SIRT3 knockout mice 
on a standard chow diet; however SIRT3-/- mice were 
only mildly distinguishable from WT littermates [14].  
As they aged however, 13 month old SIRT3 knockout 
mice showed accelerated signs of aging in the heart, 
including cardiac hypertrophy and fibrosis [18]. In 
addition, SIRT3 knockout mice were also 
hypersensitive to cardiac stress induced by transverse 
aortic constriction (TAC), and to cancer [19]. 
Simultaneously, Someya et al. demonstrated that SIRT3 
mediates protective effects of caloric restriction on age-
related hearing loss by promoting the mitochondrial 
antioxidant system through regulation of isocitrate 
dehydrogenase 2 (Idh2) [20]. Qiu et al. illustrated that 
protective effects of caloric restriction (CR) on 
oxidative stress and damage are diminished in mice 
lacking SIRT3 [21]. SIRT3 reduces cellular ROS levels 
dependent on superoxide dismutase 2 (SOD2), a major 
mitochondrial antioxidant enzyme.  Additionally, liver 
phenotypes appear to be mediated by SIRT3. Recent 
studies have demonstrated that during fasting, SIRT3-/- 
mice have diminished fatty acid oxidation, develop a 
fatty liver, have low levels of ATP production, and 
show a defect in thermogenesis and hypoglycemia 
during a cold test [22]. SIRT3 activates hepatic lipid 
catabolism via deacetylation of LCAD, a central 
enzyme in the fatty acid oxidation process. Similar 
phenotypes have been established in mice lacking the 
mitochondrial enzyme AceCS2—(it is also acetylated 
by SIRT3 [23]), which suggest that SIRT3 is an 
important adaptive signal during fasting. Hepatic SIRT3 
protein expression increases during fasting [24], 
therefore both its protein levels and enzymatic activities 
are elevated during nutrient deprivation. 
 
SIRT3 activity and NAD levels are suppressed in 
livers of obese animals.  
 
Compared to caloric restriction, relatively little is 
known about the role of sirtuins and acetylation under 
conditions of caloric excess. Our recent study [25] adds 
to the understanding of SIRT3 metabolic function in the 
context of metabolic stress induced by high fat diet and 
obesity. We fed a chronic (up to 16 wk) high fat diet 
(HFD) to mice and demonstrated reduced SIRT3 
activity in their livers, a 3-fold decrease in hepatic 
NAD+ levels, and increased mitochondrial protein 
oxidation.  Using a targeted proteomics approach, we 
elucidated 193 proteins that were preferentially 
acetylated in mice on HFD compared to controls, 
including 11 proteins not previously identified in 
acetylation studies. HFD led to hyperacetylation of 
proteins involved in gluconeogenesis, mitochondrial 
oxidative metabolism, methionine metabolism, liver 
injury, and ER stress response. In contrast, neither 
SIRT1 nor histone acetyltransferase (HAT) activities 
were altered, implicating SIRT3 as a dominant factor 
contributing to the observed phenotype. Compared to 
wild-type mice, SIRT3-deficient animals demonstrated 
an even greater hyperacetylation of gluconeogenic and 
mitochondrial proteins under HFD conditions. In 
corroboration with increased acetylation, mice lacking 
SIRT3 demonstrated a disruption of mitochondrial 
oxidative phosphorylation complexes II, III, and V. This 
is the first study to identify acetylation patterns in liver 
proteins of HFD mice and suggests that SIRT3 and 
hyperacetylation may play an important role in the 
regulation of cellular and mitochondrial metabolism 
induced by high-fat feeding.   
 
The study raises several important questions. Increased 
mitochondrial protein oxidation in the livers of HFD-
fed mice is consistent with higher levels of production 
of mitochondrial ROS under stress conditions [26, 27], 
and suggests that hyperacetylation could play an 
important role in suppressing function of oxidative 
stress defense enzymes contributing to HFD-induced 
liver injury. In mice on HFD, reduced SIRT3 activity 
was highly correlated with reduced NAD+ levels as the 
animals became obese. However, the regulatory 
mechanisms for reduced NAD biosynthesis and 
distribution of NAD precursors affecting specific 
sirtuins remain undetermined.  Likewise, could the 
biosynthesis of NAD intermediates and metabolites be 
effective therapeutic targets and/or reagents for 
mitochondrial disorders and other diseases?   Obesity 
and fatty liver disease are characterized by the 
paradoxical accumulation of triglycerides in the insulin-
resistant liver [28]. Strong evidence suggests that the 
maintenance of NAD+ concentration is required for 
normal mitochondrial fatty acid oxidation [28, 29]. It 
has been shown that pharmacological stimulation of 
mitochondrial NADH oxidation dramatically promotes 
beta-oxidation and ameliorates dyslipidemia, adiposity, 
and fatty liver in obese mice [28]. Nampt 
overexpression has been shown to maintain cellular 
NAD levels and thereby stimulates sirtuin activity, 
resulting in protection of cardiac myocytes from 
poly(ADP-ribose)polymerase (PARP)-induced cell 
death during heart failure [30]. Lastly, since diminished 
mitochondrial function may play a pivotal role in 
mechanisms regulating insulin resistance, non-alcoholic 
fatty liver disease, and other metabolic disorders, it 
remains to be seen whether specific molecular agonists 
for SIRT3 activity can reverse metabolic disorders such 
as obesity, type 2 diabetes mellitus and/or inflammatory 
complications of a high fat diet. If rescuing SIRT3 
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dietary high fat feeding, it will add to the growing body 
of evidence suggesting that sirtuins might be potential 
pharmacological targets, not only for extending life 
span but also for treating metabolic syndrome.  
 
To date, most studies on the biological functions of 
sirtuins have been conducted in cell culture and mouse 
models, with studies on possible correlations between 
human plasma. Therefore, more work needs to be done 
to elucidate the physiological relevance of sirtuins in 
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